BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22945654)

  • 1. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers.
    Siu MK; Wong ES; Kong DS; Chan HY; Jiang L; Wong OG; Lam EW; Chan KK; Ngan HY; Le XF; Cheung AN
    Oncogene; 2013 Jul; 32(30):3500-9. PubMed ID: 22945654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
    Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
    Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.
    Siu MK; Chan HY; Kong DS; Wong ES; Wong OG; Ngan HY; Tam KF; Zhang H; Li Z; Chan QK; Tsao SW; Strömblad S; Cheung AN
    Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18622-7. PubMed ID: 20926745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.
    Wang Y; Sheng Q; Spillman MA; Behbakht K; Gu H
    Oncogene; 2012 May; 31(20):2512-20. PubMed ID: 21996746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
    Qin S; Li Y; Cao X; Du J; Huang X
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer.
    Zhou B; Xu H; Xia M; Sun C; Li N; Guo E; Guo L; Shan W; Lu H; Wu Y; Li Y; Yang D; Weng D; Meng L; Hu J; Ma D; Chen G; Li K
    Front Med; 2017 Jun; 11(2):214-222. PubMed ID: 28470508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.
    Sellar GC; Li L; Watt KP; Nelkin BD; Rabiasz GJ; Stronach EA; Miller EP; Porteous DJ; Smyth JF; Gabra H
    Cancer Res; 2001 Oct; 61(19):6977-81. PubMed ID: 11585719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway.
    Zhu W; Niu J; He M; Zhang L; Lv X; Liu F; Jiang L; Zhang J; Yu Z; Zhao L; Bi J; Yan Y; Wei Q; Huo H; Fan Y; Chen Y; Ding J; Wei M
    J Transl Med; 2019 Aug; 17(1):259. PubMed ID: 31395064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2.
    Wu Q; Guo R; Lin M; Zhou B; Wang Y
    Gynecol Oncol; 2011 Jul; 122(1):149-54. PubMed ID: 21529905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.
    Bourguignon LY; Peyrollier K; Xia W; Gilad E
    J Biol Chem; 2008 Jun; 283(25):17635-51. PubMed ID: 18441325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TALEN-induced disruption of Nanog expression results in reduced proliferation, invasiveness and migration, increased chemosensitivity and reversal of EMT in HepG2 cells.
    Yu AQ; Ding Y; Li CL; Yang Y; Yan SR; Li DS
    Oncol Rep; 2016 Mar; 35(3):1657-63. PubMed ID: 26676719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NANOG regulates epithelial-mesenchymal transition via AMPK/mTOR signalling pathway in ovarian cancer SKOV-3 and A2780 cells.
    Yun H; Han GH; Kim J; Chung JY; Kim JH; Cho H
    J Cell Mol Med; 2022 Oct; 26(20):5277-5291. PubMed ID: 36114703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activin A promotes ovarian cancer cell migration by suppressing E-cadherin expression.
    Yi Y; Cheng JC; Klausen C; Leung PCK
    Exp Cell Res; 2019 Sep; 382(2):111471. PubMed ID: 31229504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma.
    Wang Y; Yan S; Liu X; Zhang W; Li Y; Dong R; Zhang Q; Yang Q; Yuan C; Shen K; Kong B
    Oncol Rep; 2014 Apr; 31(4):1905-10. PubMed ID: 24573236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome.
    Siu MK; Wong ES; Chan HY; Ngan HY; Chan KY; Cheung AN
    Am J Pathol; 2008 Oct; 173(4):1165-72. PubMed ID: 18772339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion.
    Li Y; Wan X; Wei Y; Liu X; Lai W; Zhang L; Jin J; Wu C; Shao Q; Shao G; Lin Q
    Oncol Rep; 2016 Jun; 35(6):3586-92. PubMed ID: 27109588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling.
    Sun Y; Fan X; Zhang Q; Shi X; Xu G; Zou C
    Tumour Biol; 2017 Jul; 39(7):1010428317712592. PubMed ID: 28718374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
    Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
    Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.